Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TOI | 8-K | neutral | 2/10 | Oncology Institute, Inc. is rebranding as Starling Oncology, Inc. effective July 28, 2026, with its Nasdaq ticker changi | Aug 3, 2026 |
| DSGN | 8-K | mixed | 5/10 | Design Therapeutics reported Q2 2026 financial results with a net loss of $20.2M ($0.32 per share), beating consensus of | Aug 3, 2026 |
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech announced that the final subject received their last dose in the Phase 2 DURIPANC trial of Ampligen for m | Aug 3, 2026 |
| PTHS | PRESS-RELEASE | neutral | 1/10 | Pelthos Therapeutics, Inc. announced it will report its Q2 2026 results on August 13, 2026. | Aug 3, 2026 |
| CADL | PRESS-RELEASE | neutral | 2/10 | Candel Therapeutics announced that an abstract on aglatimagene besadenovec in localized prostate cancer was accepted for | Aug 3, 2026 |
| DSGN | PRESS-RELEASE | bullish | 5/10 | Design Therapeutics reported Q2 2026 net loss of $0.32 per share, beating consensus of -$0.36 by 11%, and highlighted po | Aug 3, 2026 |
| SPRY | PRESS-RELEASE | neutral | 1/10 | ARS Pharmaceuticals, Inc. announced it will host a conference call on August 13 to discuss its Q2 2026 results. | Aug 3, 2026 |
| RGNX | PRESS-RELEASE | neutral | 1/10 | REGENXBIO Inc. announced it will host a conference call on August 6 to discuss its Q2 2026 results. | Aug 3, 2026 |
| KRYS | 8-K | bullish | 6/10 | Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (+24% YoY), slightly below the $121.0M consensus, with GAAP | Aug 3, 2026 |
| TGTX | 8-K | mixed | 6/10 | TG Therapeutics reported Q2 2026 total global revenue of $240.3M (up 70% YoY, beating consensus of $229.8M) and raised f | Aug 3, 2026 |
| OCUL | 8-K | bullish | 7/10 | Ocular Therapeutix reported Q2 2026 revenue of $13.5M (flat YoY) and a net loss of $(0.35) per share, which is a narrowe | Aug 3, 2026 |
| TWST | 8-K | bullish | 7/10 | Twist Bioscience reported fiscal Q3 2026 revenue of $118.4M, a 23% YoY increase and above the $114.5M consensus estimate | Aug 3, 2026 |
| ALT | PRESS-RELEASE | bullish | 6/10 | Altimmune initiated the PERFORMA Phase 3 registrational trial of pemvidutide in MASH, a key milestone following positive | Aug 3, 2026 |
| LNTH | PRESS-RELEASE | bullish | 7/10 | Lantheus Holdings has entered into a definitive agreement to be acquired by Curium US Holdings LLC for $102.50 per share | Aug 3, 2026 |
| HELP | PRESS-RELEASE | bullish | 5/10 | Helus Pharma appointed Michael Halstead as CEO effective immediately. Halstead was President of Intra-Cellular Therapies | Aug 3, 2026 |
| COCP | 8-K | mixed | 5/10 | Cocrystal Pharma entered into a $5M private placement with OPKO Health, selling 5,474,053 shares at $0.9134 per share (m | Aug 3, 2026 |
| AUTL | 8-K | neutral | 6/10 | Autolus Therapeutics entered into a $250M senior secured notes facility with Perceptive Credit Holdings, issuing an init | Aug 3, 2026 |
| BNTX | PRESS-RELEASE | neutral | 4/10 | BioNTech announced the appointment of Guido Oelkers, Ph.D., as the new CEO, effective by February 1, 2027, succeeding co | Aug 3, 2026 |
| ABBV | INST-CLUSTER | mixed | 5/10 | In Q2 2026, three institutional buyers added $270.2M to ABBV positions while three sellers trimmed $149.4M, resulting in | Aug 2, 2026 |
| ABT | COURT-RULING | neutral | 2/10 | The District of Maine granted Abbott Laboratories' motion to transfer a former employee's discrimination and retaliation | Aug 1, 2026 |
| SNY | COURT-RULING | bullish | 5/10 | The Federal Circuit affirmed the PTAB's denial of Pfizer's motion to amend patent claims in three IPR proceedings, rulin | Aug 1, 2026 |
| PFE | COURT-RULING | bearish | 4/10 | The Federal Circuit affirmed the PTAB's denial of Pfizer's motion to amend claims in its pneumococcal vaccine patent (U. | Aug 1, 2026 |
| KLRA | COURT-RULING | neutral | 1/10 | Kailera Therapeutics (KLRA) filed a lawsuit against Structure Therapeutics, Inc. in the Northern District of California. | Aug 1, 2026 |
| TEVA | COURT-RULING | bullish | 7/10 | Teva won summary judgment dismissing United Healthcare's RICO claims as time-barred. The court held that storm warnings, | Aug 1, 2026 |
| IONS | INSIDER-BUY | neutral | 4/10 | Director Michael Hayden made two open-market purchases of IONS stock totaling $1.06M on July 30-31, 2026, at prices betw | Aug 1, 2026 |
| IQV | CLUSTER | neutral | 2/10 | CEO Ari Bousbib and CFO Eric Sherbet sold a combined $2.35M in open-market transactions on July 29, 2026, following IQVI | Aug 1, 2026 |
| LLY | COURT-RULING | bearish | 7/10 | The Michigan Supreme Court overruled two long-standing precedents (Smith and Liss) that had broadly exempted regulated i | Aug 1, 2026 |
| GRDX | S-1/A | bearish | 6/10 | GridAI Technologies Corp. filed Amendment No. 2 to its S-1 registration statement to register the resale of 9,908,766 sh | Jul 31, 2026 |
| AVXL | PREC14A | mixed | 7/10 | Anavex Life Sciences is facing a contested proxy fight with activist investor PVG Asset Management, which has nominated | Jul 31, 2026 |
| VRXA | F-1 | bearish | 6/10 | Veraxa Biotech AG filed an F-1 registration statement to register up to 25,000,000 ordinary shares for resale by Lincoln | Jul 31, 2026 |